The Human Growth Hormone Market registered a market size of USD 4,632.54 million in 2020 and is expected to reach USD 7,567.74 million by 2026, registering a CAGR of 8.61 % during the forecast period.
According to a research article by Mohamed Hamdy Elkarow et al., published in Frontiers in Endocrinology Journal November 2020, patients with decreased growth hormone secretion constitute a risk factor for COVID-19 severity, which requires attention towards preventive measures in susceptible individuals.
In addition, patients with Prader-Willi syndrome should take extra precautions to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not show typical symptoms such as a high temperature and they may also experience a higher-than-normal pain threshold which may delay in the diagnosis of COVID-19.
The major factors driving the market growth include development of recombinant human growth hormone drugs, rise in pituitary dysfunction cases and rising off-label use of human growth hormone.
In humans the growth hormone deficiency is caused when the pituitary gland does not synthesize enough concentration of human growth hormone. This deficiency is treated by administering recombinant human growth hormone by subcutaneous injection. Various genetic disorders such as Prader-Willi syndrome and Turner syndrome, may also cause growth hormone deficiency leading to delayed puberty and shorter-than-average height.
Turner syndrome also known as Congenital ovarian hypoplasia syndrome, occurs when the X chromosome is partially or completely missing in females. According to a research article by Xiaoxiao Cui et al., published in Intractable & Rare Diseases Research Journal 2018, globally, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 female live births.
The human growth hormone helps to stimulate regeneration, reproduction and growth. Rising use of growth hormone and awareness about the growth hormone which helps in the management of growth hormone deficiency disorderswhich is boosting the market growth.
Furthermore, most companies are investing in R&D for developing a growth hormone that has fewer side effects and will be long-acting hormonal therapy. In addition, rapid developments of new novel recombinant human growth hormone is expected to drive the human growth hormone market, over the forecast period.
Key Market Trends
Turner Syndrome Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Turner syndrome is a rare chromosomal disorder that affects females. It is characterized by the partial or complete loss of one of the X chromosomes. The symptoms of Turner syndrome include a wide neck and a low or indistinct hairline, a tendency to develop high blood pressure, minor eye problems, drooping of the eyelids, and an under-active thyroid gland.
Individuals with Turner syndrome are at higher risk for severe illness from the COVID-19 virus. In addition, Turner syndrome patients often present with congenital heart disease, including having a bicuspid aortic valve. Heart disease is an underlying medical condition that can result in severe complications from COVID-19.
According to a research article by Xiaoxiao Cui et al. published in Intractable & Rare Diseases Research 2018, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 female live births. It is highly prevalent in China.
Since Turner syndrome is associated with many complications related to heart, autoimmune disorders, mental health issues, hearing loss, infertility, and pregnancy complications, the demand for treatment involving growth hormones is increasing which is boosting the market growth.
Increasing awareness about early diagnosis and treatment of Turner syndrome by various public and private organizations is expected to boost the market growth. For instance, non-profit organizations such as Turner Syndrome Support Society United Kingdom, Turner Syndrome Society of the United States and Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" in February every year and launched a nationwide campaign to spread awareness about the condition.
Furthermore, increasing research and development in the development of effective therapeutics for Turner syndrome (TS) shows positive impact on market growth. For instance, as per research study published in Intractable & Rare Diseases Research 2018, the next generation of treatment for Turner syndrome (TS) will be based on stem cells and regenerative medicine. Thus, considering above factors it is expected to show significant growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
The major factors driving the market growth in the United States include increasing research and development activities, favorable reimbursement policies, established healthcare infrastructure, significant government initiatives, and growing healthcare awareness.
As per Foundation for Prader-Willi Research registry data August 2020, in people with Prader-Willi Syndrome, the COVID-19 showed impact on access to medical care and therapies due to COVID-19-related restrictions in United States. In addition, due to COVID-19 related restrictions showed impact on temporarily access to physical, occupational, speech, and psychological therapies. There was a 60-80% decline in access to Prader-Willi Syndrome related therapies.
According to a research article by Jessica Bohonowych et al., published in Genes Journal 2019, Prader-Willi syndrome (PWS) is a rare genetic disorder with an estimated prevalence of approximately 10,000 to 20,000 living individuals in the United States.
As per the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the United States. Recombinant growth hormone has been widely available for chronic renal insufficiency, growth hormone deficiency (GHD), gestational age or intrauterine growth retardation, Turner's syndrome, Prader-Willi syndrome, and cachexia in the United States.
Furthermore, increasing awareness about growth hormone deficiencies and treatment is expected to boost the market growth. For instance, every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates Children's growth awareness day to spread awareness about the early diagnosis and treatment of growth hormone disorders.
Increasing research and development activities in the development of effective therapeutics resulting in increasing number of pipeline drugs. For instance, in October 2019, Pfizer Inc. and its partner OPKO Health Inc. announced that its Phase III study investigating Somatrogon in pre-pubertal children with human growth hormone met its primary endpoint of non-inferiority to daily somatropin. Thus, owing to above factors it is expected to show growth over the forecast period.
The Human Growth Hormone Market is moderately consolidated, with a few market players controlling a significant market share. Furthermore, there are several active partnerships for the development of more efficacious and long-acting subtypes of human growth hormones. Some of the key market players include AnkeBio Co. Ltd, Eli Lilly and Company, Ferring BV, Novo Nordisk AS, Ipsen S.A., Pfizer Inc, Genentech, Inc (Roche) and Teva Pharmaceutical Industries, Ltd.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Development of Recombinant Human Growth Hormone Drugs
- 4.2.2 Rise in Pituitary Dysfunction Cases
- 4.2.3 Rising Off-label Use of Human Growth Hormone
- 4.3 Market Restraints
- 4.3.1 Adverse Effects Associated with Human Growth Hormone
- 4.3.2 Stringent Regulatory Processes
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Application
- 5.1.1 Growth Hormone Deficiency
- 5.1.2 Turner Syndrome
- 5.1.3 Idiopathic Short Stature
- 5.1.4 Prader-Willi Syndrome
- 5.1.5 Other Applications
- 5.2 By Distribution Channel
- 5.2.1 Hospital and Retail Pharmacy
- 5.2.2 Online Pharmacy
- 5.2.3 Other Distribution Channels
- 5.3 By Geography
- 5.3.1 North America
- 22.214.171.124 United States (By Application and By Distribution Channel)
- 126.96.36.199 Canada (By Application and By Distribution Channel)
- 188.8.131.52 Mexico (By Application and By Distribution Channel)
- 5.3.2 Europe
- 184.108.40.206 Germany (By Application and By Distribution Channel)
- 220.127.116.11 United Kingdom (By Application and By Distribution Channel)
- 18.104.22.168 France (By Application and By Distribution Channel)
- 22.214.171.124 Italy (By Application and By Distribution Channel)
- 126.96.36.199 Spain (By Application and By Distribution Channel)
- 188.8.131.52 Rest of Europe (By Application and By Distribution Channel)
- 5.3.3 Asia-Pacific
- 184.108.40.206 China (By Application and By Distribution Channel)
- 220.127.116.11 Japan (By Application and By Distribution Channel)
- 18.104.22.168 India (By Application and By Distribution Channel)
- 22.214.171.124 Australia (By Application and By Distribution Channel)
- 126.96.36.199 South Korea (By Application and By Distribution Channel)
- 188.8.131.52 Rest of Asia-Pacific (By Application and By Distribution Channel)
- 5.3.4 Middle East and Africa
- 184.108.40.206 GCC (By Application and By Distribution Channel)
- 220.127.116.11 South Africa (By Application and By Distribution Channel)
- 18.104.22.168 Rest of Middle East and Africa (By Application and By Distribution Channel)
- 5.3.5 South America
- 22.214.171.124 Brazil (By Application and By Distribution Channel)
- 126.96.36.199 Argentina (By Application and By Distribution Channel)
- 188.8.131.52 Rest of South America (By Application and By Distribution Channel)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 AnkeBio Co. Ltd
- 6.1.2 EMD Serono Inc.
- 6.1.3 F.Hoffmann-La Roche Ltd
- 6.1.4 Ferring BV
- 6.1.5 Ipsen S.A.
- 6.1.6 Eli Lilly and Company
- 6.1.7 Novo Nordisk AS
- 6.1.8 Pfizer Inc.
- 6.1.9 Teva Pharmaceutical Industries Ltd
- 6.1.10 Sandoz International GmbH (Novartis AG)
- 6.1.11 Strongbridge Biopharma
- 6.1.12 GeneScience Pharmaceuticals Co. Ltd
- 6.1.13 Sinobioway Hygene Biomedicine Co., Ltd
- 6.1.14 Aeterna Zentaris
- 6.1.15 LG Life Sciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS